BCDA News and Press, BioCardia Inc. From 06/14/21

SAN CARLOS, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today announced it is to join the Russell Microcap ® Index. This milestone w...

SAN CARLOS, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer Peter Altman will present a corporate ov...

SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its qua...

SAN CARLOS, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese biotechnology company related to BioCardia Helix catheter biotherapeutic delivery product candidates.  Unde...

BioCardia (BCDA): FY GAAP EPS of -$1.48.Revenue of $0.15M (-78.9% Y/Y)Shares -3.28% PM.Press Release For further details see: BioCardia reports FY results

SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative therapies, today reported financial results for the fourth quarter and full year ended ...

BioCardia has a leading-edge cardiac cell therapy platform. The company recently announced a settlement Term Sheet with Boston Scientific, BSX. They are funded through Q3 2022. 29% Inside Ownership. For further details see: BioCardia Is Super Cheap With Multiple Shot...

SAN CARLOS, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese pharmaceutical company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under th...

SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced clinical leadership changes. Dr. Sujith Shetty who has been wit...

Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...